Postpartum depression affects about one in seven women after childbirth, with symptoms ranging from persistent sadness and anxiety to difficulty bonding with the baby. Standard treatment includes therapy and antidepressants like sertraline, which can take weeks to work. A new FDA-approved drug, brexanolone, works within days but requires a 60-hour hospital infusion.
What's actually going on in research
Trials are testing oral versions of drugs that target the brain's response to reproductive hormones, rapid-acting treatments that work in days rather than weeks, and digital interventions that reach mothers at home. Researchers are also studying whether treating depression during pregnancy prevents postpartum depression, and whether specific biomarkers can predict who will develop severe symptoms.
Oral neurosteroid drugs
Following brexanolone's success, newer pills that work on the same hormone pathway are in late-stage trials. These could offer rapid relief without hospital admission.
Prevention trials
Studies are testing whether starting antidepressants during the third trimester prevents postpartum depression in high-risk women. Early data suggest this approach may reduce severe episodes.
Digital therapy platforms
Smartphone-based programs deliver cognitive behavioral therapy to new mothers at home. Trials are measuring whether these tools work as well as in-person therapy and reach women who can't access traditional care.
What to know before you search
Eligibility typically depends on symptom severity, timing since delivery, whether you're breastfeeding, and any prior depression history.
What types of trials are currently open
- Treatment trials — Testing new medications, often rapid-acting drugs or oral versions of brexanolone, against standard antidepressants.
- Prevention trials — Testing whether treatment during pregnancy or immediately after delivery can prevent postpartum depression in at-risk women.
- Digital intervention studies — Testing smartphone apps, online therapy programs, and telehealth approaches that deliver treatment without clinic visits.
- Therapy trials — Comparing different forms of counseling, often adapted specifically for postpartum depression and the demands of new motherhood.
- Biomarker studies — Following pregnant and postpartum women to identify hormone levels, genetic markers, or other factors that predict who will develop depression.
Recently added Postpartum Depression trials
A Study of MI078 for Postpartum Depression
This is a multicenter, randomized, double-blind, placebo-controlled trial consisting of an experimental drug group and a placebo group, each enrolling 100 participants. The objective of this study is to assess the efficacy and safety of MI078 capsules for the treatment of postpartum depression.
Feasibility and Acceptability of a Novel Digital Intervention to Prevent Paternal Postpartum Depression
Postpartum depression (PPD) occurs almost as often among men as it does among women. However, while there have been multiple programs designed to prevent maternal PPD, few, if any, interventions exist that have been created specifically to prevent paternal PPD. After engaging in evidence-based qualitative research with soon-to-be or new fathers, a novel interpersonal-therapy based digital program was created to prevent paternal PPD called Together in Parenting (TIP), which comprises multiple podcasts and digital educational handouts. The proposed pilot study will examine the feasibility and acceptability of using TIP as a paternal PPD intervention, will determine the optimal timing of administering TIP to future/new fathers, and will generate preliminary estimates of effect of the intervention to support a future efficacy study.
Find Postpartum Depression trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.